常见肿瘤规范化、标准化诊治第2讲晚期大肠癌的药物治疗

下载PDF

导出

作者巴一黄鼎智王华庆

机构地区天津医科大学肿瘤医院

出处《中国医刊》 CAS 2007年第9期28-31,共4页 Chinese Journal of Medicine

关键词晚期大肠癌药物治疗标准化肿瘤诊治分子靶向药物化疗药物大肠癌患者

参考文献6

1Grothey A,Sargent D,Goldberg RM,et al.Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin,irinotecan,and oxaliplatin in the course of treatment[J].J Clin Oncol,2004,22(7):1209-1214.
2Grothey A,Sargent D.Overall survival of patients with advanced colorectal cancer (CRC) correlates with availability of 5-fluorouracil,irinotecan,and oxaliplatin regardless of whether doublet or single agent therapy is used first-line[C].San Francisco:Program and abstracts of the 2006 Gastrointestinal Cancers Symposium,2006.282.
3Goldberg RM,Sargent DJ,Morton RF,et al.A randomized controlled trial of fluorouracil plus leucovorin,irinotecan,and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer[J].J Clin Oncol,2004,22:23-30.
4Douillard JY,Cunningham D,Roth AD,et al.Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer:a multicentre randomised trial[J].Lancet,2000,355:1041-1047.
5Tournigand C,Andre T,Achille E et al.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:a randomized GERCOR study[J].J Clin Oncol,2004,22:229-237.
6Peeters M,Van Custem E,Sienna S,et al.A phase 3 multicenter randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients with metastatic colorectal cancer[C].American Association for Cancer research 2006 Annual Meeting,2006.

中国医刊

2007年第9期

内容加载中请稍等...